Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ross Stores, Inc. (ROST) vs Viatris Inc (VTRS) Price & Performance

Ross Stores, Inc.Trade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Ross Stores, Inc. vs Viatris Inc — how do they compare? Ross Stores, Inc. trades at $225.95 (market cap $73.25B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Ross Stores, Inc. is far larger — about 3.8× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.

ROSTVTRS
Market Cap
$73.25B$19.09B
Sector
Consumer CyclicalHealth
52-Week High
$255.23$17.86
52-Week Low
$144.67$9.49
Enterprise Value
$73.70B$31.21B
Dividend Yield
0.78%2.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ross Stores, Inc.

Ross Stores (ROST) trades at $229.31, down 0.6% on the day, showing bearish technical signals despite strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.66 beating expectations by 36%. Revenue growth accelerated to 13% in Q2 2026, with comparable store sales surging 10% driven by increased traffic and margin expansion. The stock faces technical resistance near $234 while maintaining strong analyst support with a $271.33 consensus price target.

ROST presents a compelling growth story with robust fundamentals but faces near-term technical headwinds. The company's value-focused retail strategy resonates with cost-conscious consumers, driving consistent earnings outperformance. Key risks include competitive pressures in off-price retail and macroeconomic sensitivity. With 64% of analysts maintaining buy ratings and a 19% upside to consensus targets, the stock offers growth potential for investors comfortable with current technical weakness.

Viatris Inc

Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.

The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ross Stores, Inc.

Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach

Read more on ROST

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS